PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment

被引：0
|
作者：
Linhua Jin
Yoko Tabe
Kensuke Kojima
Masato Shikami
Juliana Benito
Vivian Ruvolo
Rui-Yu Wang
Teresa McQueen
Stefan O. Ciurea
Takashi Miida
Michael Andreeff
Marina Konopleva
机构：
[1] Juntendo University School of Medicine,Department of Clinical Laboratory Medicine
[2] The University of Texas MD Anderson Cancer Center,Department of Leukemia
[3] Aichi Medical University,Department of Hematology
[4] The University of Texas MD Anderson Cancer Center,Department of Stem Cell Transplantation and Cellular Therapy
来源：
Journal of Molecular Medicine | 2013年 / 91卷
关键词：
Acute myeloid leukemia; Bone marrow microenvironment; Hypoxia; Apoptosis; GDC-0941; ABT-737;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1383 / 1397
页数：14
相关论文
共 50 条
  • [21] The PI3K inhibitor GDC-0941 is synergistic with lapatinib, and mediates endocrine sensitivity in uterine papillary serous carcinoma
    Levano, Kelly S.
    Rodriguez-Gabin, Alicia
    Goldberg, Gary L.
    Horwitz, Susan B.
    Hou, June Y.
    CANCER RESEARCH, 2014, 74 (19)
  • [22] PI3k inhibitor GDC-0941 synergizes with standard of care therapies to induce growth inhibition and apoptosis of multiple myeloma cells
    Ebens, Allen
    Du, Changchun
    Slaga, Dion
    Munugalavadla, Veerendra
    Sun, Laura
    Berry, Leanne
    Mariathasan, Sanjeev
    CANCER RESEARCH, 2009, 69
  • [23] The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells
    Munugalavadla, Veerendra
    Berry, Leanne
    Du, Changchun
    Mariathasan, Sanjeev
    Slaga, Dion
    Sun, Laura
    Chesi, Marta
    Bergsagel, Peter Leif
    Ebens, Allen J.
    BLOOD, 2009, 114 (22) : 1456 - 1456
  • [24] Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics
    Kikuchi, Hugh
    Amofa, Eunice
    Mcenery, Maeve
    Schey, Steve Arthur
    Ramasamy, Karthik
    Farzaneh, Farzin
    Calle, Yolanda
    CANCERS, 2023, 15 (02)
  • [25] The Class I Selective PI3K Inhibitor GDC-0941 Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing the Rate of Apoptosis
    Wallin, J. J.
    Guan, J.
    Prior, W. W.
    Lee, L. B.
    Ross, L.
    Belmont, L. D.
    Koeppen, H.
    Belvin, M.
    Sampath, D.
    Friedman, L. S.
    CANCER RESEARCH, 2012, 72
  • [26] Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
    Junttila, Teemu T.
    Akita, Robert W.
    Parsons, Kathryn
    Fields, Carter
    Phillips, Gail D. Lewis
    Friedman, Lori S.
    Sampath, Deepak
    Sliwkowski, Mark X.
    CANCER CELL, 2009, 15 (05) : 429 - 440
  • [27] Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
    Hoeflich, Klaus P.
    Merchant, Mark
    Orr, Christine
    Chan, Jocelyn
    Den Otter, Doug
    Berry, Leanne
    Kasman, Ian
    Koeppen, Hartmut
    Rice, Ken
    Yang, Nai-Ying
    Engst, Stefan
    Johnston, Stuart
    Friedman, Lori S.
    Belvin, Marcia
    CANCER RESEARCH, 2012, 72 (01) : 210 - 219
  • [28] Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel PI3K inhibitor GDC-0941
    Salphati, Laurent
    Belvin, Marcia
    Edgar, Kyle
    Prior, Wei Wei
    Sampath, Deepak
    Wallin, Jeffrey
    Wong, Harvey
    DRUG METABOLISM REVIEWS, 2009, 41 : 164 - 164
  • [29] Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment
    Jin, Linhua
    Tabe, Yoko
    Lu, Hongbo
    Borthakur, Gautam
    Miida, Takashi
    Kantarjian, Hagop
    Andreeff, Michael
    Konopleva, Marina
    CANCER LETTERS, 2013, 329 (01) : 45 - 58
  • [30] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Shapiro, Geoffrey, I
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Rudin, Charles M.
    Kurkjian, Carla
    Cleary, James M.
    Pilat, Mary Jo
    Jones, Suzanne
    de Crespigny, Alex
    Fredrickson, Jill
    Musib, Luna
    Yan, Yibing
    Wongchenko, Matthew
    Hsieh, Hsin-Ju
    Gates, Mary R.
    Chan, Iris T.
    Bendell, Johanna
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 419 - 432
12345